CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to PFE

Macugen ™ (pegaptanib sodium injection)

Phase 2
PFIZER (PFE)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Macular Degeneration

View Full Landscape
Drug Information

Target Indication

Macular Degeneration

Clinical Trial

NCT00087763

Last updated: 10/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA1/31/2006

Macugen

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.